NIH Starts Clinical Trial with ONC206, a Next-Generation Imipridone
A first patient has been treated in a first-in-human clinical trial of Oncoceutic’s next-generation imipridone ONC206 at the NIH. Please find more information here.
-
Our Team
Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.Learn more -
Our Science
Our approach uses a new class of compounds called imipridones that selectively target G protein-coupled receptors (GPCRs) and ClpP to control critical signaling pathways in cancer.Learn more -
Alliances
MD Anderson Cancer Center and Massachusetts General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.Learn more
In The News
-
NOV 03 2020
-
-
OCT 09 2020
DRD2-mediated preclinical efficacy of ONC201 in endometrial cancer
DRD2 is overexpressed in endometrial cancer and confers poor prognosis. DRD2 antagonism by ONC201 elicits efficacy in an endometrial cancer genetic mouse model. Please find the full paper here.
-
Press Releases
Events
Business Development
© Copyright 2020 Oncoceutics, Inc. All Rights Reserved.